James R. Rigas

Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer

Timothy Winton, Robert B. Livingston, David C. Johnson et al. · New England Journal of Medicine · 2005 · 1.8K citations · Full text

Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer

Román Pérez-Soler, Abraham Chachoua, Lisa A. Hammond et al. · Journal of Clinical Oncology · 2004 · 1.1K citations · Full text

Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

David Planchard, Benjamin Besse, Harry J.M. Groen et al. · The Lancet Oncology · 2016 · 867 citations · Full text

Multicentre Phase 2, Medicine, Metronomic Therapy +6

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

René Bruno, Darcy A. Hille, A. Riva et al. · Journal of Clinical Oncology · 1998 · 418 citations

Secondary Prevention of Venous Thromboembolic Events in Patients With Active Cancer: Enoxaparin Alone Versus Initial Enoxaparin Followed by Warfarin for a 180-Day Period

Steven R. Deitcher, Craig M. Kessler, Geno J. Merli et al. · Clinical and Applied Thrombosis/Hemostasis · 2006 · 392 citations

Active Cancer, Pharmacotherapy, Cancer Patients +17